• icon+90(533) 652 66 86
  • iconnwsa.akademi@hotmail.com
  • icon Fırat Akademi Samsun-Türkiye

Article Details

Article Details

  • Article Code : FIRAT-AKADEMI-7676-5587
  • Article Type : Araştırma Makalesi
  • Publication Number : 3A0097
  • Page Number : 1-16
  • Doi : 10.12739/NWSA.2023.18.1.3A0097
  • Abstract Reading : 538
  • Download : 87
  • Share :

  • PDF Download

Issue Details

  • Year : 2023
  • Volume : 18
  • Issue : 1
  • Number of Articles Published : 1
  • Published Date : 1.01.2023

Cover Download Context Page Download
Dergi Kapağı
Physical Sciences

Serial Number : 3A
ISSN No. : 1308-7304
Release Interval (in a Year) : 4 Issues

Aysel SARI1 , Zhiyan Muhammed Shaker Ahmed2

Keywords

STUDY OF SERUM GHRELIN LEVEL IN PATIENTS WITH DIABETES MELLITUS TYPE 2: IN RELATION WITH INSULIN LEVEL

Aysel SARI1 , Zhiyan Muhammed Shaker Ahmed2

Ghrelin is an orexigenic hormone. It has a suppressive effect on insulin release from pancreatic islets. In T2DM patients, hyperinsulinemia, lower ghrelin levels are observed. Total ghrelin levels in fasting plasma were lower in T2DM patients than in non-diabetic patients. It was aimed to consider serum ghrelin windows in the T2DM patient and control. It was observed that ghrelin diabetes experiments in general patient groups were estimated to be lower (262.37±129.29pg/mL), (487.40±53.81pg/mL) compared to the control group (p<0.001). Patient group insulin (27.39±11.06µU/mL) and control settings (12.07±5.49µU/mL) (p<0.001). It also shows high yield positive rates with ghrelin and insulin history (p<0.001, r=-0.699). Significantly improved performance with serum ghrelin and insulin, culprit glucose and HbA1C. A significant relationship between ghrelin and insulin and T2DM has been investigated in this comprehensive context, and there is a content relationship between ghrelin and insulin.

Keywords
Ghrelin, Insulin, Type 2 Diabetes, Plasma, Serum,

Details
   

Authors

Aysel SARI (1) (Corresponding Author)
Fırat Üniversitesi
ayselsari@hotmail.com | 0000-0002-4966-2254

Zhiyan Muhammed Shaker Ahmed (2)

Duhok specialized center for laboratory
zhiyanakreyi@yahoo.com | 0000-0003-0668-2316

Supporting Institution

 :

Project Number

 :

Thanks

 :
References
[1] Zimmet, P., Alberti, K.G., and Shaw, J., (2001). Global and societal implications of the diabetes epidemic. Nature, 414:782-787.

[2] Wild, S., Gojka Roglic, G., Green, A., Sicree, R., and Kinget, H., (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27(5):1047-1053.

[3] Charbonnel, B. and Cariou, B., (2011). Obesity, and metabolism, pharmacological management of type 2 diabetes: the potential of incretin based therapies. Diabetes, Obesity and Metabolism, 13(2):99-117.

[4] Jansen, J., Karges, W., and Rink, L., (2009). Zinc and diabetes-clinical links and molecular mechanisms. The Journal of Nutritional Biochemistry, 20(6):399-417.

[5] Vos, T., et al., (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study. Lancet, 390(10100):1211-1259.

[6] Care, A.D.A.J.D., (2014). Diagnosis and classification of diabetes mellitus. Diabetes Care, 37(1):81-90.

[7] Olokoba, A.B., Obateru, O.A., and Olokoba, L.B., (2012). Type 2 diabetes mellitus: a review of current trends. Oman Medical Journal, 27(4):269–273.

[8] American Diabetes Association, (2015). Standards of medical care in diabetes-2015 abridged for primary care providers. Clinical Diabetes, 33(2):97–111.

[9] Abdul-Ghani, M.A., Tripathy, D., and DeFronzo, R.A., (2006). Contributions of ß-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care, 29(5):1130-9.

[10] Wege Dias, N., (2018). Strategies to improve fertility of bos taurus beef females enrolled in estrous synchronization protocols. Journal of Animal Science, 87(9):2806-14.

[11] Saudek, C.D., William H Herman, W.H., Sacks, D.B., Bergenstal, R.M., Edelman, D., and Davidson, M.B., (2008). A new look at screening and diagnosing diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism, 93(7):2447-53.

[12] Rohlfing, C.L., Wiedmeyer, H.M., Little, R.R., England, J.D., Alethea Tennill, A., and Goldstein, D.E., (2002). Defining the relationship between plasma glucose and hba1c: analysis of glucose profiles and Hba(1c); in the diabetes control and complications trial. Diabetes Care, 25(2):275-8.

[13] Ferrara, A., (2007). Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care, 30(l2):141-146.

[14] Gauna, C., Meyler, F.M., Janssen, J.A.M.J.L., Delhanty, P.J.D., Abribat, T., Van Koetsveld, P., Hofland, L.J., Broglio, F., Ghigo, E., and Van Der Lely, A.J., (2004). Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. The Journal of Clinical Endocrinology & Metabolism, 89(10):5035-42.

[15] Gottero, C., Prodam, F., Destefanis, S., Benso, A., Gauna, C.,Me, E., Filtri, L., Riganti, F., and Van Der Lely, A.J., (2004). Cortistatin-17 and-14 exert the same endocrine activities as somatostatin in humans. The Journal of Clinical Endocrinology & Metabolism, 14(5):382-387.

[16] Cowley, M.A., et al., (2003). The distribution and mechanism of action of ghrelin in the cns demonstrates a novel hypothalamic circuit regulating energy homeostasis. Journal of Clinical Endocrinology and Metabolism, 37(4):649-661.

[17] Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., and Kangawa, K., (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. The Journal of Clinical Metabolism, 402(6762):656-60.

[18] Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., and Matsukura S., (2001). A role for ghrelin in the central regulation of feeding. Nature, 409(6817):194-8.

[19] McFarlane, M.R., Brown, M.S., Goldstein, J.L., and Zhao T.J., (2014). Induced ablation of ghrelin cells in adult mice does not decrease food intake, body weight, or response to high-fat diet. The Journal of Biological Chemistry, 20(1):54-60.

[20] Zorrilla, E.P., Iwasaki, S., Moss, J.A., Chang, J., Otsuji, J., Inoue,K., Meijler, M.M., and Janda, K.D., (2006). Vaccination against weight gain. Proceedings of the National Academy of Sciences of the United States of America, 29, 103(35):13226-31.

[21] Zigman, J.M., Bouret, S.G., and Andrews, Z.B., (2016)., Obesity impairs the action of the neuroendocrine ghrelin system. Trends Endocrinol Metabolism, 27(1):54-63.

[22] Zhao, T.J., Liang, G., Li, R.L.., Xuefen, X., Sleeman, M.W., Murphy, A.J., Valenzuela, D.M., Yancopoulos, G.D., Goldstein, J.L., and Brown, M.S., (2010). Ghrelin o-acyltransferase (goat) is essential for growth hormone mediated survival of calorie-restricted mice. The Journal of Clinical Endocrinology & Metabolism, 107(16):7467-7472.

[23] Lutter, M., Sakata, I., Lawrence, S.O., Rovinsky, S.A., Anderson, J.G., Jung, J.G., Birnbaum, S., Yanagisawa, M., Elmquist, J.K., Nestler, E.J., and Zigma, J.M., (2008). The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nature Neuroscience, (7):752-3.

[24] Kojima, M. and Kangawa, K.J.P.R., (2005). Ghrelin: structure and function. Physiological Reviews, 5 Apr, 85(2):495-522.

[25] Van den Berghe, G., (2000). Novel insights into the neuroendocrinology of critical illness. The European Journal of Endocrinology, 143(1):1-13.

[26] Baldelli, R., Otero, X.L., Camiña, J.P., Gualillo, O., Popovic, V., Dieguez, C., and Casanueva, F.F., (2001). Growth hormone secretagogues as diagnostic tools in disease states. Endocrine, 14(1):95-9.

[27] Deghenghi, R., Broglio, F., Papotti, M., Muccioli, G., and Ghigo, E., (2003. Targeting the ghrelin receptor. Endocrine, 22(1:13-8.

[28] Arvat, E., Vito, L.D., Broglio, F., Papotti, M., Muccioli, G., Dieguez, C., Casanueva, F.F., Deghenghi, R., Camanni, F., and Ghigo, E., (2000). Preliminary evidence that ghrelin, the natural gh secretagogue (ghs)-receptor ligand, strongly stimulates gh secretion in humans. The Journal of Clinical Endocrinology & Metabolism, 23(8):493-5.

[29] Peino, R., Baldelli, R., Garcia, J.R., Segade, S.R., Kojima, M., Kangawa, K., Arvat, E., Ghigo, E., Dieguez, C., and Casanueva, F.F., (2000). Ghrelin-induced growth hormone secretion in humans. The European Journal of Endocrinology, 143(6):11-4.

[30] Hataya, Y., Akamizu, T., Takaya, K., Kanamoto, N., Ariyasu, H., Saijo, M., Moriyama, K., Shimatsu, A., Kojima, M., Kangawa, K., and Nakao K., (2001). A low dose of ghrelin stimulates growth hormone (gh) release synergistically with gh-releasing hormone in humans. The Journal of Clinical Endocrinology and Metabolism, 86(9):4552.

[31] Bays, H., (2004). Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obesity Research, 12(8):1197-1211.

[32] Muccioli, G., Tschöp, M., Papotti, M., Deghenghi, D., Heiman, M., and Ghigo, E., (2002). Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. European Journal of Pharmacology, 440(2-3):235-54.

[33] Masuda, Y., Tanaka, T., Inomata, N., Ohnuma, N., Tanaka, S.,Itoh, Z., Hosoda, H., Kojima, M., and Kangawa, K., (2000). Ghrelin stimulates gastric acid secretion and motility in rats. Biochemical and Biophysical Research Communications, 5;276(3):905-8.

[34] Trudel, L., Tomasetto, C., Rio,C.M., Bouin, M., Plourde, V., Eberling, P., and Poitras, P., (2002). Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. American Journal of Physiology-Gastrointestinal and Liver Physiology, 282(6):948-52.

[35] Konturek, P.C., Brzozowski, T., Pajdo, R., Nikiforuk, A., Kwiecien, S., Harsch, I., Drozdowicz, D., Hahn, E.G., and Konturek, S.J., (2004). Ghrelin-a new gastroprotective factor. Medicine, 55(2):325-336.

[36] Sibilia, V., Rindi, G., Pagani, F., Rapetti, D., Locatelli, V., Torsello, A., Campanini, N., Deghenghi, R., and Netti C., (2003). Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action. Endocrinology, 144(1):353-9.

[37] Baldanzi, G., Filigheddu, N., Cutrupi, S., Catapano, F., Bonissoni, S., Fubini, A., Malan, D., Baj, G., Granata, R., Broglio, F., Papotti, M., Surico, N., Bussolino, F., Isgaard, J., Deghenghi, R., Sinigaglia, F., Prat, M., Muccioli, G.,Ghigo, E., and Graziani, A., (2002). Ghrelin and desacyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and pi 3-kinase/AKT. Journal of Cell Biology, 23, 159(6):1029-37.

[38] Chang, L., Ren, Y., Liu, X., Li, W.G., Yang, J., Geng, B., Weintraub, N.L., and Tang, C., (2004). Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. Journal of Cardiovascular Pharmacology, 43(2):165-70.

[39] Chang, L., Ren, Y., Liu, X., Li, W.G., Yang, J., Geng, B., Weintraub, N.L., and Tang. C., (2004). Ghrelin protects myocardium from isoproterenol-induced injury in rats. Acta Pharmacologica Sinica, 25(9):1131-7.

[40] Hanada, T., Toshinai, K., and Nakazato, M., (2004). Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. Metabolism, 53(1):84-88.

[41] Hanada, T., Toshinai, K., Kajimura, N., Ashizawa, N.N., Tsukada, T., Hayashi, Y., Osuye, K., Kangawa, K., Matsukura, S., and Nakazato, M., (2003). Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochemical and Biophysical Research Communications, 301(2):275-279.

[42] Cummings, D.E., Purnell, J.O., Frayo, R.S., Schmidova, K., Wisse, B.E., Weigle, D.S., (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes, 50(8):1714-9.

[43] Tschöp, M., Wawarta, R., Riepl, R.L., Friedrich, S., Bidlingmaier, M., Landgraf, R., and Folwaczny, C., (2001). Post-prandial decrease of circulating human ghrelin levels. The Journal of Endocrinological Investigation, 24(6):19-21.

[44] Shiiya, T., Nakazato, N., Mizuta, M., Date, Y., Mondal, M.S., Tanaka, M., Nozoe, S.I., Hosoda, H., Kenji Kangawa, K.,and Matsukura, S.,(2002). Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. The Journal of Clinical Endocrinology & Metabolism, 87(1):240-4.

[45] McCowen, K., Maykel, J., and Ling, P., (2002). Circulating ghrelin concentrations are lowered by intravenous glucose or hyperinsulinemic euglycemic conditions in rodents. Diabetologia, 175(2):7-11.

[46] Tanaka, M., Naruo, T., Yasuhara, D., Tatebe, Y., Nagai, N., Shiiya, T., Nakazato, M., Matsukura, S., and Nozoe, S., (2003). Fasting plasma ghrelin levels in subtypes of anorexia nervosa. Psychoneuroendocrinology, 28(7):829-35.

[47] Soriano-Guillén, L., Barrios, V., and Argente, J., (2004). Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. The Journal of Pediatrics, 144(1):36-42

[48] Barkan, A.L., Dimaraki, E.V., Jessup, S.K., Symons, K.V., Ermolenko, M., and Jaffe, C.A., (2003). Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. The Journal of Clinical Endocrinology & Metabolism, 88(5):2180-2184.

[49] Davis, M.E., Pemberton, C.J., Yandle, T.G., Lainchbury, J.G., Rademaker, M.T., Nicholls, M.G., Frampton, C.M., and Richards, A.M., (2004). Urocortin-1 infusion in normal humans. The Journal of Clinical Endocrinology & Metabolism, 89(3):1402-1409.

[50] Qi, X., Reed, J., George H., and Greeley, J.R., (2003). Evidence that growth hormone exerts a feedback effect on stomach ghrelin production and secretion. Experimental Biology and Medicine, 228 (9):1028-1032.

[51] Chan, J.L., Bullen, J., Lee, J.H., Yiannakouris, N., and Mantzoros, C.S., (2004). Ghrelin levels are not regulated by recombinant leptin administration and/or three days of fasting in healthy subjects. The Journal of Clinical Endocrinology & Metabolism, 89(1):335-43.

[52] Gharraf, H.S, AlHadidy, A., and AlNehr, I., (2019). Study of leptin and ghrelin serum levels in patients with obstructive sleep apnea. The Egyptian Journal of Chest Diseases and Tuberculosis, 68:567-74.

[53] Tschöp, M., Smiley, D.L., and Heiman, M.L., (2000). Ghrelin induces adiposity in rodents. Nature, 407:908–913.

[54] Brimijoin, S., Chen, V.P., Pang, Y.P., Geng, L., and Gao, Y., (2016). Physiological roles for butyrylcholinesterase: a bche-ghrelin axis. Chemico-Biological Interactions, 25, 259:271-275.

[55] Pöykkö, S.M., Kellokoski, E., Hörkkö, S., Kauma, H., Kesäniemi, Y., and Ukkola, O., (2003). Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes mellitus. Diabetes, 52(10):2546-53.

[56] Ramirez, L. and Hamad, A.R.A., (2015). From non-obese diabetic to network for the pancreatic organ donor with diabetes: new heights in type 1 diabetes research. World Journal of Diabete, 25, 6(16):1309-11.

[57] Wilcox, G.J.C.B.R., (2005). Insulin and insulin resistance. The Clinical Biochemist Reviews 26(2):19-39.

[58] Hosoda, H., et al., (2004). Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clinical Chemistry, 50(6):1077-80.

[59] Rosenfeld, L.J., (2002). Insulin: discovery and controversy. Clinical Chemistry, 48(12):2270-2288.

[60] Alberti, K.G.M.M., Zimmet, P., and DeFronzo, R.A., (1997). International Textbook of Diabetes Mellitus. Jonathon Wiley, 24(5):451-63.

[61] Schröder, D.J.E. and Zühlke, H., (1982). Gene technology, characterization of insulin gene and the relationship to diabetes research. Endokrinologie, 79(2):197-209.

[62] Chan, S.J. and Steiner, D., (2000). Insulin through the ages: phylogeny of a growth promoting and metabolic regulatory hormone. American Zoologist, 40(2): 213-222.

[63] Petersen, M.C. and Shulman, G.I., (2018). Mechanisms of Insulin Action and Insulin Resistance. Physiological Reviews, 98(4):2133-2223.

[64] Cefalu, W.T., (2001). Insulin Resistance: cellular and clinical concepts. Experimental Biology and Medicine, 226(1):13-26.

[65] Syed, M.A., Barinas-Mitchell, E., Pietropaolo, S.L., Zhang, Y. J., Henderson, T. S., Kelley, D. E., Korytkowski, M. T., Donahue, R. P., Tracy, R. P., Trucco, M., Kuller, L.H., and Pietropaolo, M., (2002). Is type 2 diabetes a chronic inflammatory/autoimmune disease? Diabetes Nutrition & Metabolism, 15(2):68-83.

[66] Ripsin, C.M., Kang, H., and Urban, R.J., (2009). Management of blood glucose in type 2 diabetes mellitus. American Family Physician, 1, 79(1):29-36.

[67] Vijan, S.J. (2010). In The Clinic. Type 2 Diabetes. Annals of Internal Medicine, 2, 152(5):131-15.

[68] Voet, D., Voet, J.G., and Pratt, C.W., (2016). Fundamentals of Biochemistry: life at the molecular level. John Wiley & Sons. Fundamentals of Biochemistry PDF 5th Edition.1184.

[69] Stryer, L., (1995). Biochemistry. 4th Edition, W.H. Freeman and Company, New York. Biochemistry, 1184 Pages.

[70] Sah, S.P., Singh, B., Choudhary, S., and Kumar, A., (2016). Animal models of insulin resistance: A Review. Pharmacological Reports, 68(6):1165-1177.

[71] Pinkney, J.J., (2014). The role of ghrelin in metabolic regulation. Current Opinion in Clinical Nutrition and Metabolic Care, 17(6):497-502.

[72] Ukkola, O.J., (2011). Ghrelin in type 2 diabetes mellitus and metabolic syndrome. Molecular and Cellular Endocrinology, 20, 340(1):26-8.

[73] Farajallah, A., Ahmed, A., Ibrahim, N.A., Abusnana, S., and Andrew, P., (2014). The relationship between type 2 diabetes and total ghrjournal of pharmachy. IOSR Journal of Pharmacy and Biological Sciences, 4(6):2250-3013.

[74] Czech, M.P., (2017). Insulin action and resistance in obesity and type 2 diabetes. Nature Medicine, 11, 23(7):804-814.

[75] Shebl, T.H., Azeem, N.E.D.A., Younis, H.A., and Soliman, A.M., (2016). Relationship between serum leptin concentration and insulin resistance syndrome in patients with type 2 diabetes mellitus. Journal of Current Medical Research and Practice, 2(2):125.

[76] Al Qarni, A.A., Joatar, F.E.J., Das, N., Awad, M., Eltayeb, M., Al-Zubair, A.G., Ali, M.E., Masaud, A.A., Shire, A.M., Gumaa, K., and Giha H.A., (2017). Association of plasma ghrelin levels with insulin resistance in type 2 diabetes mellitus among saudi subjects. Endocrinol Metabolism (Seoul), 32(2):230-240.

[77] Zheng, Y., Ley, S.H., and Hu, F.B., (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology, 14(2):88-98.